The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
The combined company will offer laboratory testing and digital technologies for diagnosing and managing lupus, multiple sclerosis, and other autoimmune diseases.
Of the 27 companies in the index, 12 firms' share prices retreated last month, 14 companies' stocks increased, and one firm's share value was flat.
The company also received a contract from the Henry M. Jackson Foundation for a separate sepsis test.
A study by clinicians at St. Louis's Barnes-Jewish Hospital found that staff overrode alerts designed to warn of unnecessary lab testing roughly half the time.
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
The deals follow a pair of other recent acquisitions by Precision for Medicine in the artificial intelligence technology and biomarker analysis fields.
The diagnostic can now be used to identify patients with esophageal squamous cell carcinoma who may benefit from first-line treatment with Keytruda.
The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.